# TACE Combined With Sintilimab and Bevacizumab for Unresectable HCC

> **NCT04592029** · PHASE1 · UNKNOWN · sponsor: **Second Affiliated Hospital of Guangzhou Medical University** · enrollment: 36 (actual)

## Conditions studied

- Hepatocellular Carcinoma Non-resectable

## Interventions

- **DRUG:** TACE combined with sintilimab and bevacizumab

## Key facts

- **NCT ID:** NCT04592029
- **Lead sponsor:** Second Affiliated Hospital of Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-27
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-12-31
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2021-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04592029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04592029, "TACE Combined With Sintilimab and Bevacizumab for Unresectable HCC". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04592029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*